Showing 1421-1430 of 1655 results for "".
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476948/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated significantly in the equity r
- The Maze of Vision Loss and Depression in Older Adultshttps://modernod.com/news/the-maze-of-vision-loss-and-depression-in-older-adults/2476619/“The association between vision loss and depression is a complex conundrum,” Alan R. Morse, JD, PhD, President and CEO of Lighthouse Guild, said in a commentary on the challenges of vision loss and depression in older adults, published today in JAMA O
- Allergan, Mohawk Tribe Ask for Supreme Court Review of Scrutinized Patent Casehttps://modernod.com/news/allergan-mohawk-tribe-ask-for-supreme-court-review-of-scrutinized-patent-case/2476180/Allergan and the St. Regis Mohawk Tribe aim to continue their legal battle in defense of a controversial patent agreement struck a little over a year ago, appealing last week to the Supreme Court to review a federal appeals court decision which had undermined the deal’s main r
- Acuity Pro Launches Acuity Ten Digital Software and Systemhttps://modernod.com/news/acuity-pro-launches-acuity-ten-digital-software-and-system/2476187/The new Acuity Pro Ten digital visual acuity system is built with future-proofing in mind. Written in a new language, the program looks and feels very familiar with user-interface enhancements designed for ease-of-use, according to a company news release. To keep up with Windows updates and the r
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- Rayner’s New UK-Based Manufacturing Facility Receives FDA Approvalhttps://modernod.com/news/rayners-new-uk-based-manufacturing-facility-receives-fda-approval/2479988/The FDA has approved Rayner’s Ridley Innovation Centre, a $40 million purpose-built R&D, training and production facility in Worthing, UK, according to a company news release. This state-of-the-art, dedicated IOL production center has the capability of manufacturing 3 million IOLs each
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe